Notice of Annual Meeting of Shareholders 2022

AFT Pharmaceuticals Limited, Level 1, 129 Hurstmere Road, Takapuna, Auckland 0622, New Zealand
Incorporated in New Zealand ARBN 609 017 969



Notice of Annual Meeting of Shareholders 2022


Notice is hereby given that the Annual Meeting of shareholders of AFT Pharmaceuticals Limited (AFT or
the Company) will be held at the Milford Cruising Club, 24 Craig Road, Milford, Auckland, New Zealand,
on Friday, 5 August 2022 commencing at 10.30am (New Zealand time).

Agenda

A Addresses

Our Chairman, David Flacks, and our Founder and Chief Executive Officer, Hartley Atkinson, will
provide an overview of the Company’s performance for the year ended 31 March 2022. There will
also be an opportunity for shareholders to ask questions.

B Resolutions

Shareholders will be asked to consider, and if thought fit, pass the following ordinary resolutions:

1. That the directors are authorised to fix the fees and expenses of Deloitte as
auditor for the 2023 financial year.

2. That Dr Hartley Atkinson be re-elected as a director of AFT Pharmaceuticals Limited.

3. That Mr Jon Lamb be re -elected as a director of AFT Pharmaceuticals Limited.

Each resolution is an ordinary resolution and must be approved by a simple majority of the votes of
those shareholders entitled to vote and voting on the resolution.


See explanatory notes on each resolution below. No shareholder is restricted from voting on any
resolution.

The Board recommends unanimously that you vote in favour of all resolutions.

C General Business

To consider any other matter that may be brought properly before the Annual Meeting.


By Order of the AFT Pharmaceuticals Limited Board




David Flacks
Chairman

5 July 2022

Page | 2

Explanatory Notes


Resolution 1: Auditor’s Remuneration
Deloitte is automatically reappointed auditor of
the Company at the Annual Meeting pursuant
to the Companies Act 1993. The resolution
sought is to authorise the directors to fix the
remuneration of the auditor pursuant to section
207(S)(a) of the Companies Act 1993.
Resolution 2: Re-election of Dr Hartley Atkinson
as a Director
Hartley was appointed as an executive director
by the shareholders of AFT on 4 September 1997
and was last re-elected in 2019. In accordance
with the applicable NZX listing rules and the
Company’s constitution, Hartley retires by
rotation and, being eligible, offers himself for
re-election as a director of AFT at the meeting.
The Board unanimously supports Hartley's re-
election and considers Hartley to be a non-
independent director as he is an executive
officer and majority shareholder of AFT.

Dr Hartley Atkinson
Founder, Executive Director and Chief Executive
Officer
Hartley founded AFT in 1997. Before founding
AFT, Hartley worked at Swiss multinational
pharmaceutical company, Roche, for eight
years where he held positions as Sales &
Marketing Director, Medical Director, Product
Manager and Medical Manager. Prior to his
work at Roche, Hartley was a Drug Information
Pharmacist and Researcher at the Department
of Clinical Pharmacology, Christchurch Hospital.
Hartley holds a Doctorate in Pharmacology, a
Masters in Pharmaceutical Chemistry with
distinction, and a Degree in Pharmacy, all from
the University of Otago
Hartley is the current Chief Executive Officer
and a majority shareholder of AFT.

Resolution 3: Election of Mr Jon Lamb as a
Director
Jon was appointed as a director by the
shareholders of AFT on 4 September 2012, and
was last re -elected in 2019. In accordance with
the applicable NZX listing rules and the
Company’s constitution, Jon retires by rotation
and, being eligible, offers himself for re-election
as a director of AFT at the meeting. The Board
unanimously supports Jon’s re-election and
considers Jon to be an independent director.
Jon Lamb
Independent Director
Jon has led the strategic planning, marketing and
restructuring of various companies throughout his
career. He has held various roles at Beecham (a
multinational pharmaceutical company that would
later merge with a predecessor company to
GlaxoSmithKline) including CEO in New Zealand and
Marketing Manager in both Australia and South
Africa. He has also held roles as Chief Executive
Officer of Nylex in New Zealand, Managing Director
within the Rural Division of Fletcher Challenge,
Director of Southland Frozen Meats and Marketing
Director of the New Zealand Kiwifruit Marketing
Board (where he was responsible for creating the
Zespri brand of kiwifruit, and restructuring Zespri into
a retail focussed operation).
More recently, Jon was a Director of Virionyx, a New
Zealand company that developed an antiviral drug
designed to combat AIDS. He was Deputy Chair of
Australian diagnostic company ATF Group that
developed a real time tool for measuring the
Hepatitis B virus in individual patients.
Jon has been involved with AFT since 2004, firstly as a
consultant, and then in his current capacity as a
director. Jon is a Member of the Institute of Directors
and has a Diploma from the Marketing Institute of the
UK (now the Chartered Institute of Marketing).

Page | 3

Important Information



Attendance at Meeting
All shareholders registered on the Company’s
share register at 5pm on Wednesday
3 August 2022 are entitled to attend and vote
at the meeting.
Voting and Proxies
Voting at the meeting shall be by way of a poll
of the Company's shareholders entitled to vote
and voting.
A shareholder entitled to attend and vote at
the meeting can appoint a proxy to attend and
vote on that shareholder’s behalf. A proxy
need not be a shareholder. The Chair of the
meeting may be appointed to act as proxy.
If the Chair of the meeting is appointed to act
as proxy and is not directed how to vote, the
Chair will vote in favour of all the resolutions.
If you do not name a person as your proxy but
otherwise complete the proxy form in full or your
named proxy does not attend the meeting, the
Chairman will act as your proxy and will only
vote in accordance with your express direction.
A shareholder wishing to appoint a proxy can
do so by visiting www.investorvote.co.nz
.
Shareholders will be required to enter their
CSN/Holder Number and postcode or country
of residence to complete the online
appointment.
Alternatively, shareholders can appoint a proxy
by completing the enclosed proxy form and
returning it to Computershare Investor Services
Limited by any of the methods specified on the
proxy form.
The proxy form must be received no later than
10.30am on Wednesday 3 August 2022 (being
48 hours prior to the meeting).




Webcast
The Annual Meeting will be webcast live. To view and
listen to the webcast, please visit
https://webcast.openbriefing.com/8727/
Note that shareholders joining by webcast will not be
able to vote at the meeting or ask questions. In order to
vote you will need to appoint a proxy in accordance
with the above instructions before 10.30am on
Wednesday 3 August 2022.
If you have any questions you would like
considered at the meeting, please send them to
investor.relations@aftpharm.com
in advance of
the meeting.
More Information
If you have any questions, or for more
information, please contact AFT’s Company
Secretary, at investor.relations@aftpharm.com